Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC₅₀ of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3. Antitumor agent-55 induces G1/S phase arrest and apoptosis in PC3^[1].

Antitumor agent-55 (compound 5q) shows inhibitory activity against MCF-7, PC3, MGC-803, PC9, and WPMY-1 (normal human prostatic stromal myofibroblast cell line), with IC₅₀ values of 11.54 ± 0.18, 0.91 ± 0.31, 8.21 ± 0.50, 34.68 ± 0.67, and 48.15 ± 0.33, respectively^[1].
Antitumor agent-55 (0-10 μM, 24-72 h) significantly inhibits the proliferation of PC3 cells dose- and time-dependently^[1].
Antitumor agent-55 (0-4 μM, 24 h) increases the G1/S phase population, and dose-dependently elevates the expression of p27 protein^[1].
Antitumor agent-55 (0-4 μM, 24-48 h) dose-dependently induces the accumulation of ROS, and induces apoptosis of PC3 cells through activating the two apoptotic signaling pathways simultaneously^[1].
Antitumor agent-55 (0-1 μM, 48 h) effectively inhibits the wound healing and the migration of PC3 cells in a dose-dependent manner^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

598.72

C₃₂H₃₄N₆O₄S

2522594-49-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lu N, Huo JL, Wang S, Yuan XH, Liu HM. Drug repurposing: Discovery of troxipide analogs as potent antitumor agents. Eur J Med Chem. 2020;202:112471.

Antitumor agent-23 is a potent anti-cancer agent with GI₅₀s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity^[1].

Antitumor agent-23 (0.001-100 μM; 5 days) inhibits lymphoma cells proliferation^[1].
Antitumor agent-23 (2-70 nM; 72 hours) induces p53 protein expression and p53 lysine 382 acetylation (K382Ac-p53) in HPV-positive cervical cancer cell^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

506.72

C₂₈H₅₀N₄O₄

2355185-12-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Marc Labelle, et al. 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer. WO2019118973A1.

Antitumor agent-31 is a nanosized chelates of anchoring bisazo dye. Antitumor agent-31 can be used for an antioxidant and antitumor agent^[1].

468.47

C₁₈H₁₂N₈O₄S₂

2703000-00-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Abouzayed FI, et al. Synthesis of Some Novel Nanosized Chelates of Anchoring Bisazo Dye 5-[5-(4,6-Dioxo-2-thioxo-hexahydro-pyrimidin-5-ylazo)-naphthalen-1-ylazo]-2-mercapto-1H-pyrimidine-4,6-dione and Their Applications as Antioxidant and Antitumor Agents. ACS Omega. 2021;6(42):27737-27754.

Antitumor agent-19 is an antitomor agent targeting tumor-associated macrophages (TAMs) to serve as an effective TAMs modulator. The EC₅₀ values of Antitumor agent-19 in the RAW 264.7 cells and the BMDM cells are 17.18 μM and 18.87 μM, respectively^[1].

tumor-associated macrophages (TAMs)^[1]

Antitumor agent-19 (Compound 23a; 10-50 µM; 1 hour; RAW 264.7 cells) treatment effectively induces the expression of M1-phenotype macrophage markers (IL-1β, TNF-α, iNOS and IL-12α) in a dose-dependent manner. Antitumor agent-19 is found to dose-dependently repolarize TAMs from M1 (anti-tumor) and M2 (pro-tumor)^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Antitumor agent-19 (Compound 23a; 5 mg/kg; intraperitoneal injection; every other day; for 30 days; C57BL/6 female mice) is capable of remarkably inhibiting tumor growth of the LLC mouse model. Moreover, the synergy of Antitumor agent-19 with anti-PD-1 antibody has more superior antineoplastic effects than the exclusive use of either in vivo^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

487.90

C₂₄H₂₁ClF₃N₅O

2379727-90-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pei H, et al. iscovery of potent ureido tetrahydrocarbazole derivatives for cancer treatments through targeting tumor-associated macrophages. Eur J Med Chem. 2019 Sep 28;183:111741.

Antitumor agent-21 is an aryl-quinolin derivative, with potential anticancer, anti-inflammatory, anti-proliferative, anti-hormonal effects and inhibition of vasculogenic mimicry^[1][2] .

545.49

C₃₀H₂₅FNO₆P

1256037-58-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sheng-Chu Kuo, et al. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives. WO2012009519A1.

  [2]. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry. WO2016196742A1.

Antitumor agent-21 is an aryl-quinolin derivative, with potential anticancer, anti-inflammatory, anti-proliferative, anti-hormonal effects and inhibition of vasculogenic mimicry^[1][2] .

545.49

C₃₀H₂₅FNO₆P

1256037-58-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sheng-Chu Kuo, et al. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives. WO2012009519A1.

  [2]. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry. WO2016196742A1.

Antitumor agent-21 is an aryl-quinolin derivative, with potential anticancer, anti-inflammatory, anti-proliferative, anti-hormonal effects and inhibition of vasculogenic mimicry^[1][2] .

545.49

C₃₀H₂₅FNO₆P

1256037-58-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sheng-Chu Kuo, et al. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives. WO2012009519A1.

  [2]. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry. WO2016196742A1.

Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity^[1].

Antitumor agent-28 inhibits ataxia telangiectasia mutated (ATM; IC₅₀=7.6 nM; HT29 cells), ataxia telangiectasia and Rad3-related protein (ATR; IC₅₀=18 μM; HT29 cells), PI3Ka (IC₅₀=0.24 μM; BT474 cells). Antitumor agent-28 does not inhibit mTOR in MDA-MB-468 cells^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

512.62

C₂₅H₃₂N₆O₄S

2097499-67-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kurt Gordon Pike, et al. Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer. WO2017076898A1.

Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity^[1].

Antitumor agent-28 inhibits ataxia telangiectasia mutated (ATM; IC₅₀=7.6 nM; HT29 cells), ataxia telangiectasia and Rad3-related protein (ATR; IC₅₀=18 μM; HT29 cells), PI3Ka (IC₅₀=0.24 μM; BT474 cells). Antitumor agent-28 does not inhibit mTOR in MDA-MB-468 cells^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

512.62

C₂₅H₃₂N₆O₄S

2097499-67-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kurt Gordon Pike, et al. Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer. WO2017076898A1.

Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity^[1].

Antitumor agent-28 inhibits ataxia telangiectasia mutated (ATM; IC₅₀=7.6 nM; HT29 cells), ataxia telangiectasia and Rad3-related protein (ATR; IC₅₀=18 μM; HT29 cells), PI3Ka (IC₅₀=0.24 μM; BT474 cells). Antitumor agent-28 does not inhibit mTOR in MDA-MB-468 cells^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

512.62

C₂₅H₃₂N₆O₄S

2097499-67-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kurt Gordon Pike, et al. Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer. WO2017076898A1.

Antitumor agent-62 (Compound 47) is a NO-releasing antitumor agent. Antitumor agent-62 shows antiproliferative activity against four cancer cell lines. Antitumor agent-62 activates mitochondrial apoptosis pathway and arrests cell cycle at G2/M phase^[1].

Antitumor agent-62 (Compound 47) shows antiproliferative activity with IC₅₀ values of 1.23 ± 0.10, 1.91 ± 0.14, 2.81 ± 0.13, 4.18 ± 0.15 and 9.16 ± 0.38 μM against MDA-MB-231, MCF-7, HepG2, A549 and LO2 cells, respectively^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

489.46

C₂₁H₁₉N₃O₉S

2460735-29-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shi Z, et al. Novel NO-releasing scopoletin derivatives induce cell death via mitochondrial apoptosis pathway and cell cycle arrest. Eur J Med Chem. 2020 Aug 15;200:112386.

Antitumor agent-63 (Compound 40), a 20 (S)-O-linked camptothecin (CPT) glycoconjugate, is an antitumor agent without toxicity towards normal cells. Antitumor agent-63 shows high stability and very weak direct topoisomerase I (Topo I) inhibition^[1].

Antitumor agent-63 (Compound 40) shows cytotoxicity activities with IC₅₀ values of 1.2, 0.8, 30.5 and >100 µM against HepG2, HCT-116, SW1990 and HEK-293, respectively^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

846.79

C₃₈H₄₆N₄O₁₈

1627600-90-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li M, et al. Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Sep 15;202:112509.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Li M, et al. Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Sep 15;202:112509.

Antitumor agent-29 is a novel hepatocyte-targeting antitumor prodrug, which exhibits good antitumor activity and low toxic side effects.

1621.74

C₇₁H₉₆N₁₆O₂₄S₂

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang M, et al. Development of Asialoglycoprotein-Mediated Hepatocyte-Targeting Antitumor Prodrugs Triggered by Glutathione. J Med Chem. 2021 Oct 14;64(19):14793-14808.

Antitumor agent-29 is a novel hepatocyte-targeting antitumor prodrug, which exhibits good antitumor activity and low toxic side effects.

1621.74

C₇₁H₉₆N₁₆O₂₄S₂

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang M, et al. Development of Asialoglycoprotein-Mediated Hepatocyte-Targeting Antitumor Prodrugs Triggered by Glutathione. J Med Chem. 2021 Oct 14;64(19):14793-14808.

Antitumor agent-29 is a novel hepatocyte-targeting antitumor prodrug, which exhibits good antitumor activity and low toxic side effects.

1621.74

C₇₁H₉₆N₁₆O₂₄S₂

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang M, et al. Development of Asialoglycoprotein-Mediated Hepatocyte-Targeting Antitumor Prodrugs Triggered by Glutathione. J Med Chem. 2021 Oct 14;64(19):14793-14808.

Antitumor agent-59 (Compound 13b) is a potent antitumor agent. Antitumor agent-59 effectively inhibits the proliferation and migration of HCT116 cells. Antitumor agent-59 induces HCT116 cell apoptosis and arrests the cell cycle at the G2/M phase^[1].

Antitumor agent-59 (Compound 13b) (72 h) shows antitumor activities with IC₅₀ values of 0.032 ± 0.0071, 0.20 ± 0.020, 0.73 ± 0.12 and 0.58 ± 0.15 μM against HCT116, MCF-7, A549 and HUVEC cells, respectively^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

770.78

C₄₃H₃₆F₂N₆O₆

2409952-04-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liang H, et al. Discovery of novel bis-evodiamine derivatives with potent antitumor activity. Bioorg Med Chem. 2022 Jul 1;65:116793.

Antitumor agent-58 (Compound C18) is an anti-tumor agent. Antitumor agent-58 effectively inhibits colony formation and cell migration of MGC-803 cells. Antitumor agent-58 induces apoptosis of MGC-803 cells through activation of the p38 and JNK signaling pathways. Antitumor agent-58 induces mitochondrial dysfunction of MGC-803 cells. Antitumor agent-58 effectively inhibits tumor growth of xenograft model bearing MGC-803 cells^[1].

567.63

C₂₇H₂₈F₃N₉S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shi XJ, et al. Discovery of tofacitinib derivatives as orally active antitumor agents based on the scaffold hybridization strategy. Eur J Med Chem. 2020 Oct 1;203:112601.

Antitumor agent-54 (Compound C11) is a 14-3-3η protein inhibitor with a K_D of 35 µM. Antitumor agent-54 shows inhibitory activities against several typical human liver cancer cell lines. Antitumor agent-54 induces cell apoptosis and G1-S cell cycle arrest with good metabolic stability^[1].

K_D: 35 µM (14-3-3η)^[1]

456.58

C₂₉H₃₂N₂O₃

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gao Z, et al. Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein. Eur J Med Chem. 2022 Apr 29;238:114402.